Skip to main content

Table 1 Conventional chemotherapy-based salvage regimens assessed in patients with R/R HL

From: Improving outcomes after autologous transplantation in relapsed/refractory Hodgkin lymphoma: a European expert perspective

Regimen(s) Patients, N Pre-ASCT response rate Survival data in overall patient group (± ASCT)
MINE [25] 100 ORR = 75% 2-year survival rate 59%
ASHAP [22] 56 ORR = 70% (CR = 34%, PR = 36%) OS, 5-year follow-up 41%
EFS, 5-year follow-up 36%
DHAP [20] 102 ORR = 88%,
(CR = 21%, PR = 67%)
NR NR
ESHAP [23] 22 ORR = 73% 50-month follow-up 32% alive and disease-free
3-year estimates OS = 35%
Disease-free = 27%
ESHAP [24] 82 ORR = 67%
(CR = 50%)
OS, 5-year follow-up 72.6%
PFS, 5-year follow-up • Pts achieving CR = 78%
• Pts achieving PR = 16%
p < 0.01)
ICE [26] 65 ORR = 88%
(CR = 26%, PR = 58%)
OS, 43-month follow-up 83%
EFS, 43-month follow-up 68%
ICE [27] R/R HL (n = 13)
non-HL (n = 62)
ORR = 89%
(CR = 29%, PR = 60%)
OS, 24-month follow-up 65% (all pts)
EFS, 24-month follow-up 42% (all pts)
ICE/aICE [35] 97 NR OS, 51-month follow-up 80%
PFS, 51-month follow-up 70%
IVE [28] 51 ORR = 84%
(CR = 60%, good PR = 8%, PR = 16%)
NR NR
IVOx [29] 34 ORR = 76% (CR = 32%) OS, 5-year follow-up 74%
EFS, 5-year follow-up 63%
GVD pre- or post-ASCT [30] 94 ASCT-naïve pts. ORR = 61%
Prior-SCT pts. ORR = 75%
OS, 3.6-year follow-up • SCT-naïve pts. median ORR = 61%
• Prior-SCT pts. ORR = 75%
EFS, 3.6-year follow-up • SCT-naïve pts. median EFS not reached, 52% progression-free at 4 years
• Prior-SCT pts. median EFS duration 8.5 months
IGEV [31] 91 CR = 53.8%, PR = 27.5% OS, 3-year follow-up 70.03%
PFS, 3-year follow-up 52.98%
BeGEV [34] 59 ORR = 83%
(CR = 73%, PR = 10%)
OS, 2-year follow-up 77.6%
PFS, 2-year follow-up 62.2%
GDP [32] 23 ORR = 69.5%
(CR = 17.3%, PR = 52.2%)
NR NR
GemOx [33] 24 ORR = 71%
(CR = 38%, PR = 33%)
OS, 3-year follow-up Median of 26 months
PFS, 3-year follow-up Median of 14 months
  1. NR not reported, Pts patients
\